Long-term treatment with Fidarestat (cas 136087-85-9) suppresses the development of diabetic retinopathy in STZ-induced diabetic rats

Add time:09/03/2019    Source:sciencedirect.com

It is important to suppress retinal vascular changes for prevention of the onset and progression of diabetic retinopathy. In the present study, we investigated the dose–response effect of an aldose reductase (AR) inhibitor, Fidarestat (cas 136087-85-9), on retinal vascular changes in the retinas of streptozotocin (STZ)-induced diabetic rats. Fidarestat (0.5, 1, and 2 mg/kg) was administered once a day, from 4 days after STZ injection, for 15 months. Microaneurysms and thickness of the basement membrane were frequently observed in the untreated diabetic group as compared to the nondiabetic control group. In addition, the number of pericytes decreased in the untreated diabetic group. Fidarestat diminished the prevalence rate of microaneurysms, basement membrane thickness and decrease in the number of pericytes, and complete suppression was observed at a dose of 2 mg/kg. Fidarestat also dose-dependently inhibited sorbitol accumulation in the retina. Furthermore, a close correlation was observed between the prevalence rate of microaneurysms and the decrease in the number of pericytes, which indicated that damage to pericytes triggers retinal vascular changes. These results suggest that fidarestat, by virtue of its long-term correction of the accelerated polyol pathway, has a potential role in preventing the progression of diabetic retinopathy.

We also recommend Trading Suppliers and Manufacturers of Fidarestat (cas 136087-85-9). Pls Click Website Link as below: cas 136087-85-9 suppliers

Prev:Original articleEffects of Fidarestat (cas 136087-85-9), an aldose reductase inhibitor, on nerve conduction velocity and bladder function in streptozotocin-treated female rats☆
Next:Effects of 15-month aldose reductase inhibition with Fidarestat (cas 136087-85-9) on the experimental diabetic neuropathy in rats)